A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.

"Declarations Ethics approval and consent to participateFor studies 20020408 (NCT00113763) and 20030194 (NCT00113776) study protocols were approved by the independent ethics committee at participating study centers, and all patients provided written, informed consent before any study-related procedures were performed. A list of the independent ethics committees that approved studies 20020408 and 20030194 is provided in Appendix E. All methods were carried out in accordance with relevant guidelines and regulations. Consent for publicationNot applicable. Competing interestsNL reports grants from Yorkshire Cancer Research, during the conduct of the study; grants from Bristol-Myers Squibb, grants from Merck, Sharpe and Dohme, outside the submitted work. MC reports to be employed by Amgen (Europe) GmbH, Rotkreuz, Switzerland, during the conduct of the study and to own Amgen stocks and options. AD has nothing to disclose. Competing interests NL reports grants from Yorkshire Cancer Research, during the conduct of the study; grants from Bristol-Myers Squibb, grants from Merck, Sharpe and Dohme, outside the submitted work. MC reports to be employed by Amgen (Europe) GmbH, Rotkreuz, Switzerland, during the conduct of the study and to own Amgen stocks and options. AD has nothing to disclose."

"Funding NL is funded by Yorkshire Cancer Research (award reference number S406NL). NL reports receiving grants from Bristol-Myers Squibb and Merck, Sharpe, and Dohme (with funding going to his institutions). MC was an employee of and own stocks in Amgen. Yorkshire Cancer Research and Amgen had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Amgen paid the article processing charge."